Showing results (41-50 of 715) with videos related to
Sort By:
Pageof 72
Seminars in Hematology|November 26, 2002
Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndromeRazelle Kurzrock, Jorge Cortes, Hagop KantarjianClinical Lymphoma & Myeloma|March 27, 2007
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitorsEhab Atallah, Hagop Kantarjian, Jorge CortesCancer|February 2, 2012
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapyXuelin Huang, Jorge Cortes, Hagop KantarjianExpert Opinion on Pharmacotherapy|September 21, 2012
Dasatinib for the treatment of Philadelphia chromosome-positive leukemiasFabio P S Santos, Jorge CortesClinical Lymphoma, Myeloma & Leukemia|January 31, 2012
Molecular resistance: an early indicator for treatment change?Carmen Fava, Hagop Kantarjian, Jorge CortesCancer|October 15, 2010
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitorsElias Jabbour, Jorge Cortes, Hagop KantarjianLeukemia & Lymphoma|October 30, 2004
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of actionElias Jabbour, Hagop Kantarjian, Jorge CortesExpert Opinion on Investigational Drugs|February 17, 2007
Clinical activity of tipifarnib in hematologic malignanciesElias Jabbour, Hagop Kantarjian, Jorge CortesExpert Opinion on Investigational Drugs|April 28, 2007
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemiasElias Jabbour, Jorge Cortes, Hagop KantarjianOncology (Williston Park, N.Y.)|June 15, 2007
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?Elias Jabbour, Jorge Cortes, Hagop KantarjianPageof 72